Not applicableUnknownNCT04202328What this trial is testingT-DM1 in HER2-positive Metastatic/Relapsed Breast CancerWho this might be right forBreast Cancer Samsung Medical Center 1,000
Testing effectiveness (Phase 2)UnknownNCT05346328What this trial is testingHER2-positive Breast Cancer Project Initiated by InvestigatorsWho this might be right forBreast Cancer Fudan University 48
Large-scale testing (Phase 3)Study completedNCT03262935What this trial is testingSYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast CancerWho this might be right forMetastatic Breast Cancer Byondis B.V. 437
Not applicableStudy completedNCT02595762What this trial is testingTreatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast CancerWho this might be right forMetastatic Breast CancerLocally Advanced Breast Cancer Hoffmann-La Roche 110
Post-approval studies (Phase 4)Study completedNCT02658734What this trial is testingTrastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a TaxaneWho this might be right forHER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer Hoffmann-La Roche 70
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211What this trial is testingStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyWho this might be right forLocally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer Gilead Sciences 654
Early research (Phase 1)Looking for participantsNCT07524322What this trial is testingStudy of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsWho this might be right forBreast CancerOvarian CancerEndometrial Cancer+6 more Regor Pharmaceuticals Inc. 63
Large-scale testing (Phase 3)UnknownNCT04924699What this trial is testingMRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast CancerWho this might be right forAdvanced Breast CancerMetastatic Breast Cancer Shanghai Miracogen Inc. 350
Large-scale testing (Phase 3)Active Not RecruitingNCT03975647What this trial is testingTucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerWho this might be right forHER2-positive Breast Cancer Seagen, a wholly owned subsidiary of Pfizer 466
Testing effectiveness (Phase 2)Study completedNCT02614794What this trial is testingTucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerWho this might be right forHER2 Positive Breast Cancer Seagen Inc. 612
Early research (Phase 1)Ended earlyNCT04042051What this trial is testingCopanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerWho this might be right forHER2-positive Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer+1 more Cancer Trials Ireland 2
Not applicableEnded earlyNCT02611310What this trial is testingObserve Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)Who this might be right forMetastatic Breast Cancer Hoffmann-La Roche 15
Not applicableApproved For MarketingNCT04220203What this trial is testingTreatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerWho this might be right forHER2-positive Breast Cancer Seagen, a wholly owned subsidiary of Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT06224673What this trial is testingARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerWho this might be right forHER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07824869What this trial is testingA Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsWho this might be right forHER2 + Breast Cancer Shanghai Henlius Biotech 90
Large-scale testing (Phase 3)Looking for participantsNCT07413939What this trial is testingRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveWho this might be right forHER2-positive Breast Cancer Hoffmann-La Roche 650
Not applicableStudy completedNCT03025711What this trial is testingOutcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab EmtansineWho this might be right forBreast Neoplasms BELEN RUIZ-ANTORAN 220
Not applicableWithdrawnNCT02616224What this trial is testingObserve Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer Hoffmann-La Roche
Not applicableNot Yet RecruitingNCT07191405What this trial is testingClinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid TumorsWho this might be right forImmunotherapyChemotherapy Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)Looking for participantsNCT04965766What this trial is testingPatritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerWho this might be right forMetastatic Breast CancerAdvanced Breast Cancer Gustave Roussy, Cancer Campus, Grand Paris 139